DSM-Firmenich Ltd
DSFIR
ISIN CH1216478797 / Valor 121647879
DSM-Firmenich Ltd
UMushroom community rating:
About company
DSM‑Firmenich Ltd is a corporate combination created by Royal DSM and Firmenich in 2023 that brings together DSM’s nutrition-ingredients business and Firmenich’s flavors-and-fragrances capabilities into a single global supplier of ingredients and sensory solutions. The company develops, manufactures and sells vitamins, micronutrients, enzymes, cultures and other nutritional and functional ingredients alongside flavors, fragrance compounds and taste‑modulation technologies, serving food and beverage manufacturers, consumer-packaged‑goods companies, the pharmaceutical and dietary‑supplement sectors, and personal‑care producers. Its operations combine application and formulation support, regulatory and technical services, R&D in ingredient and sensory science, and global manufacturing and distribution channels to deliver tailored ingredient systems and sensory solutions to industrial customers.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (15.03.2026):
DSM-Firmenich Ltd — Q4 2024 (and full-year 2024) summary: The company reported a strong full-year performance and a robust Q4, driven by organic sales growth, merger synergies and the vitamin transformation program. Pro forma FY 2024 sales were €12,799m with Adjusted EBITDA €2,118m (margin 16.5%); Q4 2024 Adjusted EBITDA was €601m (up 37%) delivering an 18.5% margin. Cash generation improved materially (Adjusted gross operating free cash flow €1,552m) and management proposed a €2.50 dividend and a €1bn share buyback while guiding to at least €2.4bn Adjusted EBITDA for 2025.
Key financials (FY 2024 & Q4 2024)
Pro forma FY 2024 sales €12,799m (+4% pro forma), organic sales growth ~6%, Adj. EBITDA €2,118m (+19%), Adj. EBITDA margin 16.5%. Q4 2024 sales €3,257m, Adj. EBITDA €601m (+37% YoY), Q4 margin 18.5%. Core adjusted net profit (pro forma) €849m (+53%).
IFRS results and balance sheet
On an IFRS basis (including Firmenich from merger date) FY 2024 net sales €12,799m, net profit from continuing operations €280m. Net debt at year-end €2,556m and cash & equivalents €2,667m.
Cash flow and working capital
Adjusted gross operating free cash flow €1,552m (up 55% YoY); sales-to-cash conversion improved to 12.1% (from 8.1%). Operating working capital improved to 27.7% of sales (end period).
Capital returns and capital structure actions
Board proposed a stable cash dividend €2.50 per share for FY 2024 and launched a new €1bn share buyback program planned to start Q2 2025 (initial €500m then expanded to €1bn upon completion of the Feed Enzymes Alliance sale). The company reiterates commitment to investment-grade ratings.
Outlook for 2025 and drivers
Outlook: Group Adjusted EBITDA of at least €2.4bn for 2025; guidance includes at least €100m from a temporary vitamin price effect tied to a supply disruption. Management expects ~€100m additional Adj. EBITDA from further synergies and ~€100m from completion of the vitamin transformation program in 2025.
Savings, synergies and transformation progress
dsm‑firmenich reports >€120m of realized merger synergies to date (target ~€350m total, ~€105m contribution in 2024) and the vitamin transformation program contributed ~€100m in 2024 (total program target ~€200m).
Q4 specifics for Animal Nutrition & Health (ANH)
ANH showed strong improvement in Q4: FY ANH Adj. EBITDA €343m (vs €128m prior year). Q4 benefited from an ~€85m temporary vitamin price effect (A & E) and normalizing vitamin profitability; ANH Q4 Adj. EBITDA margin rose to 18.9%.
Portfolio actions and transactions
Company is actively tuning its portfolio and separating Animal Nutrition & Health. In 2024 it sold yeast extracts and marine lipids and its stake in Robertet; on Feb 11, 2025 it announced sale of the Feed Enzymes Alliance stake to Novonesis for €1.5bn — proceeds expected to support buyback and portfolio strategy.
Sustainability & governance
dsm‑firmenich set ambitious, SBTi‑validated climate targets (net‑zero by 2045) and reached 95% renewable electricity in 2024, with continued focus on Scope 3 engagement and broader ESG programs.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
18044 M
Market cap (USD)
632,941
Daily traded volume (Shares)
97.88 / 96.54
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
